Nowak F, Jacquemin-Sablon A, Pierre J
INSERM CJF 93-01, Faculté de Pharmacie, Châtenay Malabry, France.
Biochem Pharmacol. 1997 Feb 7;53(3):287-98. doi: 10.1016/s0006-2952(96)00688-0.
Tyrphostins are synthetic compounds that have been described as in vitro inhibitors of epidermal growth factor receptor (EGF-R) tyrosine kinase activity. The inhibitory effect of tyrphostins in intact cells has been shown only after prolonged treatment. However, these compounds appear to be readily incorporated, which suggests that tyrphostin acts indirectly on EGF-R. We studied the effects of a tyrphostin derivative, RG 50864, without preincubation in intact epithelial cells. We selected two human cell lines differing in degree of expression of the p185erbB2 protein, which is closely related to EGF-R. We showed that tyrphostin (RG 50864) had no effect on EGF-dependent EGF-R tyrosine phosphorylation in the parental cell line. On the contrary, it prolonged the EGF-dependent EGF-R and p185erbB2(V-E) tyrosine phosphorylation in p185erbB2(V-E)-expressing cells. Because tyrphostin has been shown to be an inhibitor of p185erbB2 and EGF-R in vitro, this finding indicates that the tyrphostin effect on p185erbB2(V-E) and EGF-R was the result of an indirect mechanism in transfected cells. Tyrphostin treatment alone led to the activation of mitogen-activated protein (MAP) kinase kinase or MAP kinase or extracellular signal-regulated kinase kinase (MEK), suggesting that one of the tyrphostin targets was upstream of MEK1. MAP kinase, however, was not activated after tyrphostin treatment. This finding indicates that tyrphostin had another target in intact cells because MEK1 activation by tyrphostin alone did not correlate with MAP kinase activation. In the two cell lines, tyrphostin modified the time course of EGF-dependent MEK and MAP kinase activation. We conclude that whereas tyrphostins were designed to inhibit EGF-R tyrosine kinase activity, under our conditions EGF-R is not a physiological target for tyrphostin, nor is one of its related protein tyrosine kinases, p185erbB2(V-E). On the contrary, our results show that tyrphostin targets are multiple, leading to complex effects on receptor signaling in these epithelial cells.
tyrphostins是一类合成化合物,已被描述为表皮生长因子受体(EGF-R)酪氨酸激酶活性的体外抑制剂。仅在长时间处理后,tyrphostins对完整细胞的抑制作用才得以显现。然而,这些化合物似乎易于被整合,这表明tyrphostin间接作用于EGF-R。我们研究了一种tyrphostin衍生物RG 50864在完整上皮细胞中未经预孵育时的作用。我们选择了两种p185erbB2蛋白表达程度不同的人细胞系,该蛋白与EGF-R密切相关。我们发现tyrphostin(RG 50864)对亲代细胞系中EGF依赖性EGF-R酪氨酸磷酸化没有影响。相反,它延长了p185erbB2(V-E)表达细胞中EGF依赖性EGF-R和p185erbB2(V-E)酪氨酸磷酸化的时间。由于tyrphostin在体外已被证明是p185erbB2和EGF-R的抑制剂,这一发现表明tyrphostin对p185erbB2(V-E)和EGF-R的作用是转染细胞中间接机制的结果。单独使用tyrphostin处理会导致丝裂原活化蛋白(MAP)激酶激酶或MAP激酶或细胞外信号调节激酶激酶(MEK)的激活,这表明tyrphostin的一个靶点位于MEK1的上游。然而,tyrphostin处理后MAP激酶未被激活。这一发现表明tyrphostin在完整细胞中有另一个靶点,因为单独使用tyrphostin激活MEK1与MAP激酶激活不相关。在这两种细胞系中,tyrphostin改变了EGF依赖性MEK和MAP激酶激活的时间进程。我们得出结论,虽然tyrphostins被设计用于抑制EGF-R酪氨酸激酶活性,但在我们的实验条件下,EGF-R不是tyrphostin的生理靶点,其相关蛋白酪氨酸激酶之一p185erbB2(V-E)也不是。相反,我们的结果表明tyrphostin的靶点是多方面的,对这些上皮细胞中的受体信号传导产生复杂影响。